Human tumor cloning assay: clinical applications for ovarian, gastric, pancreatic, and colorectal cancers.
In this investigation, the human clonogenic assay is used as a tool to identify which chemotherapeutic agents may be of interest for intraperitoneal administration. Both conventional and investigational agents are examined in ovarian, colorectal, pancreatic, and gastric carcinomas. Scattergrams plotting the in vitro percent response against the in vivo percent response provide some clinical correlation with the observed in vivo antitumor activity. In addition, anticancer agents are identified for which evidence of a dose-response relationship is observed in the clonogenic assay. Such evidence is offered as the basis for the choice of agents that may be useful for intraperitoneal administration.
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003114:Colony-Forming Units Assay; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008722:Methods; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D012004:Rectal Neoplasms / Q000188:drug therapy*; D013274:Stomach Neoplasms / Q000188:drug therapy*; D014410:Tumor Stem Cell Assay
D000970:Antineoplastic Agents